Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Vinblastine Action Pathway (New)
Homo sapiens
Drug Action Pathway
Vinblastine (also named Velban) is a natural alkaloid isolated from Vinca rosea, originally from Catharanthus (vinca) roseus. Vinblastine is used as chemotherapy medication such as an antimitotic agent. It is used as a treatment of breast cancer, testicular cancer, neuroblastoma, Hodgkin's and non-Hodgkins lymphoma, mycosis fungoides, histiocytosis and Kaposi's sarcoma. Its antitumor activity is thought to be due primarly to inhibition of mitosis at metaphase through interaction its interaction with tubulin (microtubules). Vinblastine binds specifically to microtubular proteins (tubulin) of the mitotic spindle, leading to crystallization of the microtubules (not dynamic anymore). In consequence, there is a mitotic arrest leading to the cell death. The disarray of microtubules induces two proteins; cellular tumor antigen p53 and cyclin dependent kinase inhibitor p21. The latter protein works to inhibit cyclin dependent kinases in the cell, which disrupt the phosphorylation of the apoptosis inhibitor Bcl-2. Bcl-2 suppresses apoptosis by regulating permeability of the mitochondrial membrane, but is unable to do so due to the interrupted phosphorylation. The former protein, p53, acts on BAK and BAX to enact conformational changes, creating pores in the mitochondrial membrane that allow the exit of cytochrome c. Cytochrome c further activates capsases in the cell, which cleave essential cellular proteins. In this way, p53 and p21 work alongside each other to promote apoptosis and terminate unhealthy cells.
References
Vinblastine Pathway (New) References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Jordan MA, Kamath K: How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets. 2007 Dec;7(8):730-42. doi: 10.2174/156800907783220417.
Pubmed: 18220533
Correia JJ: Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther. 1991 Nov;52(2):127-47. doi: 10.1016/0163-7258(91)90004-6.
Pubmed: 1818332
Jordan A, Hadfield JA, Lawrence NJ, McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998 Jul;18(4):259-96. doi: 10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u.
Pubmed: 9664292
Fry RC: The effect of leukaemia inhibitory factor (LIF) on embryogenesis. Reprod Fertil Dev. 1992;4(4):449-58. doi: 10.1071/rd9920449.
Pubmed: 1461995
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings